All In Biotech

Drug Trial Radar · NCT04534725

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;

COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; C-SMART Study.

Last checked: Nov 20, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 441 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

441

Actual

Start

Dec 17, 2020

Primary completion

Nov 28, 2022

Study completion Apr 19, 2023

Sponsor

Lead sponsor
Peter MacCallum Cancer Centre, AustraliaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-centre Australian trial with four arms aims to evaluate several different immune modulating drugs for prevention and treatment of COVID-19 specifically in the cancer population. ARM 1 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with no COVID-19 infection or no known COVID-19 positive contacts. ARM 2 is evaluating the effect of interferon-alpha (vs placebo) on the incidence of COVID-19 infection in cancer patients with confirmed exposure to COVID-19 virus. ARM 3 is evaluating the effect of Selinexor (vs placebo) on the incidence of COVID-19 infection in cancer patients with moderate COVID-19 infection. ARM 4 is evaluating the effect of Lenzilumab (vs placebo) on the treatment of COVID-19 infection in cancer patients with severe COVID-19 infection. Participants may become eligible and transition to different arms and treatments if they become exposed to COVID-19 or are hospitalised with an active moderate/severe COVID-19 infection. It is hoped this research will provide insight into the best practice for prevention and treatment of COVID-19 in cancer patients as emerging standard of care measures are not always suitable to this especially vulnerable population.

Conditions

  • Cancer
  • Covid19
  • Respiratory Viral Infection

Interventions

  • Interferon alfaDrug

    intranasal spray

  • SelinexorDrug

    oral tablet

  • LenzilumabDrug

    intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of COVID-19 in cancer patients using interferon-alpha as prophylaxis without known positive contact with COVID-19 (COVID-19 confirmed by qPCR from respiratory swab)Time frame: 3 months from baseline.
  2. incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testingTime frame: 3 months from baseline.
  3. incidence of COVID-19 when Interferon alpha is given as post-exposure prophylaxis with a known positive contact or exposure with COVID-19. COVID-19 confirmed by qPCR from respiratory swab .Time frame: 28 days from baseline
  4. incidence of any upper or lower community acquired respiratory viral infection assessed using local standard of care testingTime frame: 28 days from baseline
  5. incidence of death and/or need for invasive or non-invasive ventilation. assessed using medical recordsTime frame: 60 days from baseline
  6. time to clinical improvement or discharge from hospital assessed using medical recordsTime frame: 28 days from baseline

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • St Vincent's Hospital

    Fitzroy, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • Royal Melbourne Hospital

    Melbourne, Victoria, Australia

  • Austin Health

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.